Rallybio Announces Reverse Stock Split of Common Stock in Connection with the Proposed Merger with Avenzo

Rallybio Corp (RLYB) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Rallybio Announces Reverse Stock Split of Common Stock in Connection with the Proposed Merger with Avenzo EAST BERLIN, Conn., November 10, 2026 – Rallybio Corporation (Nasdaq: RLYB) today announced that it will effect a one-for-two reverse stock split of its issued a

Event · Stock split
Ratio
one-for-two
Reverse split
yes
Effective
November 20, 2026

Facts are quoted from the filing text and checked against it.

Original reporting
Published Nov 10, 2026, 10:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 10:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$RLYB
Neutral
high confidence
Mentioned
$RLYB
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$RLYBNeutralMed
01

Why it matters

The split reduces share count, may improve per‑share price metrics, and sets the stage for the post‑merger ticker AVZO.

02

Market read

Primary corporate action for a small‑cap biotech; relevant for traders tracking split‑related volatility and merger outcomes.

03

What to watch

Potential Nasdaq listing requirements and cash‑in‑lieu for fractional shares could affect shareholder sentiment.

Relevance 6/10Novelty 7/10Timing: effective Nov 20 2026

Background

Rallybio (Nasdaq: RLYB) filed an 8‑K detailing a reverse stock split tied to its merger with Avenzo Therapeutics.

Company-level read

Ticker impact

$RLYBNeutralHigh confidence
Context

Rallybio announced a one‑for‑two reverse stock split and its pending merger with Avenzo, with the split effective Nov 20 2026.

Expected impact

likely pressure as the market adjusts to the split and merger timeline

Evidence & confidence

Reverse splits often trigger trading activity; the pending merger adds uncertainty, leading to modest downside risk until completion.

Market effects

Biotech sector may see slight re‑rating as Rallybio consolidates with Avenzo, potentially affecting peer valuations.

Limited to US small‑cap biotech investors; no broader regional effect.

Minimal global impact beyond niche biotech investors.

Counterpoint

If the merger proceeds smoothly, the split could be a catalyst for upside as the combined entity gains scale.

Key entities

  • Rallybio Corp

    US‑listed biotech announcing reverse split and merger.

  • Avenzo Therapeutics

    Clinical‑stage biotech merger partner.

Related articles

$RLYBHigh

Rallybio Corporation announced today that, subject to the satisfaction or waiver of any outstanding closing conditions, it anticipates the transactions…

Rallybio Corp (RLYB) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. Rallybio Corporation (the “Company”) announced today that, subject to the satisfaction or waiver of any outstanding closing conditions, it anticipates the transactions contemplated by the Agreement and Plan of Merger and Reorganization (the “Merger Agreeme

$RLYBHighAI 8/10

The Rallybio Corporation, a Delaware corporation, entered into an Agreement and Plan of Merger and Reorganization with Avenzo Therapeutics, Inc., a Delaware…

Rallybio Corp (RLYB) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. As previously disclosed, on May 31, 2026, the Rallybio Corporation, a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) with Avenzo Therapeutics, Inc., a Delaware corporation (“Av